1
|
Tahiri A, Satheesh SV, de Wijn R, Lders T, Aure MR, Quigley DA, Bukholm IR, Hurtado A, Kristensen VN, Geisler J. Abstract P6-08-05: Protein tyrosine kinase activity and miRNA expression profiling reveals differences according to progesterone-receptor-status in HER-2 negative breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-08-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Kinases are considered as promising source of biomarkers for diagnostic, prognostic and therapeutic purposes in cancer patients. We assessed tyrosine kinase activity in 39 primary breast cancer samples that were all hormone receptor positive (ER+ and/or PR+) with differential HER-2 status, using microarray technology. Methods: Pamchip® peptide microarrays were used to measure the activity of protein tyrosine kinases in 32 breast cancer samples. The breast cancer cell lines MCF-7, BT474 and ZR75-1, was studied for kinase activity, both untreated and treated with estradiol. Results: Results showed differences in phosphorylation amongst breast cancer samples. A total of 37 peptide kinases were highly phosphorylated in a group of breast cancer samples representing 33 protein tyrosine kinases involved in cancer pathways and immunological responses. In vitro studies with breast cancer cell lines exhibited the same phosphorylation profiles, but increased phosphorylation was only observed in one cell line, ZR75-1. Eliminating HER-2 positive samples, we obtained differences in phosphorylation profiles based on PR-status only. Samples lacking PR-expression exhibited higher kinase activity of downstream kinases compared to PR-positive samples. Similar results were obtained with miRNA expression profiles of 31 breast cancer samples. Five miRNAs were identified to be significantly differentially expressed (p < 0.05) between PR-negative and PR-positive samples. This effect was even stronger when eliminating HER-2 positive samples, with 13 miRNAs exhibiting significant differential expression based on PR-status. Conclusion: Although our data are based on a small dataset, the lack of PR expression seems to have a profound effect on tyrosine kinase activity and miRNA expression in HER-2 negative breast cancers without any effect on gene expression. This indicates that regulatory and functional molecules might exhibit phenotypical features of cancer that cannot be explained by gene expression alone.
Citation Format: Tahiri A, Satheesh SV, de Wijn R, Lders T, Aure MR, Quigley DA, Bukholm IR, Hurtado A, Kristensen VN, Geisler J. Protein tyrosine kinase activity and miRNA expression profiling reveals differences according to progesterone-receptor-status in HER-2 negative breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-08-05.
Collapse
Affiliation(s)
- A Tahiri
- Akershus University Hospital, Lrenskog, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Centre for Molecular Medicine Norway (NCMM), Oslo, Norway; Pamgene International B.V, 's -Hertogenbosch, Netherlands; Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Helen Diller Family Comprehensive Cancer Center, San Fransisco, CA; Akershus University Hospital, Lrenskog, Norway
| | - SV Satheesh
- Akershus University Hospital, Lrenskog, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Centre for Molecular Medicine Norway (NCMM), Oslo, Norway; Pamgene International B.V, 's -Hertogenbosch, Netherlands; Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Helen Diller Family Comprehensive Cancer Center, San Fransisco, CA; Akershus University Hospital, Lrenskog, Norway
| | - R de Wijn
- Akershus University Hospital, Lrenskog, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Centre for Molecular Medicine Norway (NCMM), Oslo, Norway; Pamgene International B.V, 's -Hertogenbosch, Netherlands; Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Helen Diller Family Comprehensive Cancer Center, San Fransisco, CA; Akershus University Hospital, Lrenskog, Norway
| | - T Lders
- Akershus University Hospital, Lrenskog, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Centre for Molecular Medicine Norway (NCMM), Oslo, Norway; Pamgene International B.V, 's -Hertogenbosch, Netherlands; Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Helen Diller Family Comprehensive Cancer Center, San Fransisco, CA; Akershus University Hospital, Lrenskog, Norway
| | - MR Aure
- Akershus University Hospital, Lrenskog, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Centre for Molecular Medicine Norway (NCMM), Oslo, Norway; Pamgene International B.V, 's -Hertogenbosch, Netherlands; Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Helen Diller Family Comprehensive Cancer Center, San Fransisco, CA; Akershus University Hospital, Lrenskog, Norway
| | - DA Quigley
- Akershus University Hospital, Lrenskog, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Centre for Molecular Medicine Norway (NCMM), Oslo, Norway; Pamgene International B.V, 's -Hertogenbosch, Netherlands; Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Helen Diller Family Comprehensive Cancer Center, San Fransisco, CA; Akershus University Hospital, Lrenskog, Norway
| | - IR Bukholm
- Akershus University Hospital, Lrenskog, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Centre for Molecular Medicine Norway (NCMM), Oslo, Norway; Pamgene International B.V, 's -Hertogenbosch, Netherlands; Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Helen Diller Family Comprehensive Cancer Center, San Fransisco, CA; Akershus University Hospital, Lrenskog, Norway
| | - A Hurtado
- Akershus University Hospital, Lrenskog, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Centre for Molecular Medicine Norway (NCMM), Oslo, Norway; Pamgene International B.V, 's -Hertogenbosch, Netherlands; Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Helen Diller Family Comprehensive Cancer Center, San Fransisco, CA; Akershus University Hospital, Lrenskog, Norway
| | - VN Kristensen
- Akershus University Hospital, Lrenskog, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Centre for Molecular Medicine Norway (NCMM), Oslo, Norway; Pamgene International B.V, 's -Hertogenbosch, Netherlands; Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Helen Diller Family Comprehensive Cancer Center, San Fransisco, CA; Akershus University Hospital, Lrenskog, Norway
| | - J Geisler
- Akershus University Hospital, Lrenskog, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Centre for Molecular Medicine Norway (NCMM), Oslo, Norway; Pamgene International B.V, 's -Hertogenbosch, Netherlands; Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Helen Diller Family Comprehensive Cancer Center, San Fransisco, CA; Akershus University Hospital, Lrenskog, Norway
| |
Collapse
|
2
|
Eftang LL, Esbensen Y, Tannæs TM, Bukholm IRK, Bukholm G. Interleukin-8 is the single most up-regulated gene in whole genome profiling of H. pylori exposed gastric epithelial cells. BMC Microbiol 2012; 12:9. [PMID: 22248188 PMCID: PMC3292955 DOI: 10.1186/1471-2180-12-9] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2011] [Accepted: 01/17/2012] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND The association between Helicobacter pylori infection and upper gastrointestinal disease is well established. However, only a small fraction of H. pylori carriers develop disease, and there are great geographical differences in disease penetrance. The explanation to this enigma lies in the interaction between the bacterium and the host. H. pylori Outer Membrane Phospholipase A (OMPLA) has been suggested to play a role in the virulence of this bacterium. The aim of this study was to profile the most significant cellular pathways and biological processes affected in gastric epithelial cells during 24 h of H. pylori exposure, and to study the inflammatory response to OMPLA⁺ and OMPLA⁻ H. pylori variants. RESULTS Interleukin-8 was the most significantly up-regulated gene and appears to play a paramount role in the epithelial cell response to H. pylori infection and in the pathological processes leading to gastric disease. MAPK and NF-kappaB cellular pathways were powerfully activated, but did not seem to explain the impressive IL-8 response. There was marked up-regulation of TP53BP2, whose corresponding protein ASPP2 may interact with H. pylori CagA and cause marked p53 suppression of apoptosis. Other regulators of apoptosis also showed abberant regulation. We also identified up-regulation of several oncogenes and down-regulation of tumor suppressor genes as early as during the first 24 h of infection. H. pylori OMPLA phase variation did not seem to influence the inflammatory epithelial cell gene response in this experiment. CONCLUSION In whole genome analysis of the epithelial response to H. pylori exposure, IL-8 demonstrated the most marked up-regulation, and was involved in many of the most important cellular response processes to the infection. There was dysregulation of apoptosis, tumor suppressor genes and oncogenes as early as in the first 24 h of H. pylori infection, which may represent early signs of gastric tumorigenesis. OMPLA⁺/⁻ did not affect the acute inflammatory response to H. pylori.
Collapse
Affiliation(s)
- Lars L Eftang
- Department of Clinical Molecular Biology (Epigen), Institute of Clinical Medicine, University of Oslo, Akershus University Hospital, Lørenskog, Norway
- Department of Gastroenterological Surgery, Akershus University Hospital, Lørenskog, Norway
| | - Ying Esbensen
- Department of Clinical Molecular Biology (Epigen), Institute of Clinical Medicine, University of Oslo, Akershus University Hospital, Lørenskog, Norway
| | - Tone M Tannæs
- Department of Clinical Molecular Biology (Epigen), Akershus University Hospital, Lørenskog, Norway
| | - Ida RK Bukholm
- Department of Gastroenterological Surgery, Akershus University Hospital, Lørenskog, Norway
- Institute of Clinical Medicine, Akershus University Hospital, University of Oslo, Lørenskog, Norway
| | - Geir Bukholm
- Institute of Health and Society, University of Oslo, Oslo, Norway
| |
Collapse
|
3
|
Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IRK, Ikdahl T, Kåresen R, Børresen-Dale AL, Jeffrey SS. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007; 9:R30. [PMID: 17504517 PMCID: PMC1929092 DOI: 10.1186/bcr1675] [Citation(s) in RCA: 217] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2006] [Revised: 03/14/2007] [Accepted: 05/15/2007] [Indexed: 12/25/2022] Open
Abstract
Introduction Gene expression profiling of breast carcinomas has increased our understanding of the heterogeneous biology of this disease and promises to impact clinical care. The aim of this study was to evaluate the prognostic value of gene expression-based classification along with established prognostic markers and mutation status of the TP53 gene (tumour protein p53) in a group of breast cancer patients with long-term (12 to 16 years) follow-up. Methods The clinical and histopathological parameters of 200 breast cancer patients were studied for their effects on clinical outcome using univariate/multivariate Cox regression. The prognostic impact of mutations in the TP53 gene, identified using temporal temperature gradient gel electrophoresis and sequencing, was also evaluated. Eighty of the samples were analyzed for gene expression using 42 K cDNA microarrays and the patients were assigned to five previously defined molecular expression groups. The strength of the gene expression based classification versus standard markers was evaluated by adding this variable to the Cox regression model used to analyze all samples. Results Both univariate and multivariate analysis showed that TP53 mutation status, tumor size and lymph node status were the strongest predictors of breast cancer survival for the whole group of patients. Analyses of the patients with gene expression data showed that TP53 mutation status, gene expression based classification, tumor size and lymph node status were significant predictors of survival. Breast cancer cases in the 'basal-like' and 'ERBB2+' gene expression subgroups had a very high mortality the first two years, while the 'highly proliferating luminal' cases developed the disease more slowly, showing highest mortality after 5 to 8 years. The TP53 mutation status showed strong association with the 'basal-like' and 'ERBB2+' subgroups, and tumors with mutation had a characteristic gene expression pattern. Conclusion TP53 mutation status and gene-expression based groups are important survival markers of breast cancer, and these molecular markers may provide prognostic information that complements clinical variables. The study adds experience and knowledge to an ongoing characterization and classification of the disease.
Collapse
Affiliation(s)
- Anita Langerød
- Department of Genetics, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway N-0310
| | - Hongjuan Zhao
- Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA
- Department of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Ørnulf Borgan
- Department of Mathematics, University of Oslo, Oslo, Norway N-0316
| | - Jahn M Nesland
- Department of Pathology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway N-0310
- Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Ida RK Bukholm
- Department of Surgery, Akershus University Hospital, Nordbyhagen, Norway N-1474
| | - Tone Ikdahl
- Cancer Center, Ullevål University Hospital, Oslo, Norway N-0407
| | - Rolf Kåresen
- Faculty of Medicine, University of Oslo, Oslo, Norway
- Department of Surgery, Ullevål University Hospital, Oslo, Norway N-0407
| | - Anne-Lise Børresen-Dale
- Department of Genetics, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway N-0310
- Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Stefanie S Jeffrey
- Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA
| |
Collapse
|
5
|
Kapp AV, Jeffrey SS, Langerød A, Børresen-Dale AL, Han W, Noh DY, Bukholm IRK, Nicolau M, Brown PO, Tibshirani R. Discovery and validation of breast cancer subtypes. BMC Genomics 2006; 7:231. [PMID: 16965636 PMCID: PMC1574316 DOI: 10.1186/1471-2164-7-231] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2006] [Accepted: 09/11/2006] [Indexed: 11/17/2022] Open
Abstract
Background Previous studies demonstrated breast cancer tumor tissue samples could be classified into different subtypes based upon DNA microarray profiles. The most recent study presented evidence for the existence of five different subtypes: normal breast-like, basal, luminal A, luminal B, and ERBB2+. Results Based upon the analysis of 599 microarrays (five separate cDNA microarray datasets) using a novel approach, we present evidence in support of the most consistently identifiable subtypes of breast cancer tumor tissue microarrays being: ESR1+/ERBB2-, ESR1-/ERBB2-, and ERBB2+ (collectively called the ESR1/ERBB2 subtypes). We validate all three subtypes statistically and show the subtype to which a sample belongs is a significant predictor of overall survival and distant-metastasis free probability. Conclusion As a consequence of the statistical validation procedure we have a set of centroids which can be applied to any microarray (indexed by UniGene Cluster ID) to classify it to one of the ESR1/ERBB2 subtypes. Moreover, the method used to define the ESR1/ERBB2 subtypes is not specific to the disease. The method can be used to identify subtypes in any disease for which there are at least two independent microarray datasets of disease samples.
Collapse
Affiliation(s)
- Amy V Kapp
- Department of Statistics, Stanford University, Stanford, CA, USA
| | - Stefanie S Jeffrey
- Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA
| | - Anita Langerød
- Department of Genetics, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway
| | - Anne-Lise Børresen-Dale
- Department of Genetics, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway
- Medical Faculty, University of Oslo, Oslo, Norway
| | - Wonshik Han
- Department of Surgery, Seoul National University College of Medicine, Seoul, Korea
| | - Dong-Young Noh
- Department of Surgery, Seoul National University College of Medicine, Seoul, Korea
| | - Ida RK Bukholm
- Department of Surgery, Akershus University Hospital, Nordbyhagen, Norway
- University of Oslo, Oslo, Norway
| | - Monica Nicolau
- Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA
| | - Patrick O Brown
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA
| | - Robert Tibshirani
- Department of Statistics, Stanford University, Stanford, CA, USA
- Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA
| |
Collapse
|